Placenta growth factor is a survival factor for human malignant mesothelioma cells

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 2, 2009, Pages 389-401

  Albonici, Loredana ^a   Doldo, E ^a   Palumbo, C ^a   Orlandi, A ^a   Bei, R ^a   Pompeo, E ^a   Mineo, T C ^a   Modesti, A ^a   Manzari, V ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Malignant mesothelioma; Placenta growth factor; Survival factor; VEGF receptors

Indexed keywords

NEUROPILIN 1; NEUROPILIN 2; PLACENTAL GROWTH FACTOR; PLACENTAL GROWTH FACTOR 2; PLACENTAL GROWTH FACTOR ANTIBODY; PROTEIN ANTIBODY; PROTEIN KINASE B; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL PROTECTION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 67650477260     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200216     Document Type: Article

References (45)

1. Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591-1603
2. Lee AY, Raz DJ, He B, Jablons DM. Update on the molecular biology of malignant mesothelioma. Cancer 2007; 109(8):1454-1461 (Pubitemid 46595678)
3. Roskoski RJr. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007; 62:179-213. (Pubitemid 46679285)
4. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res 2005; 65:550-563 (Pubitemid 40138976)
5. De Falco S, Gigante B, Persico MG. Structure and function of placental growth factor. Trends Cardiovasc Med 2002; 12:241-246 (Pubitemid 35286760)
6. Clauss M, Weich H, Breier G, Knies U, Rockl W, Waltenberger J, Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implication for a functional role of placenta growth factor in monocyte-activation and chemotaxis. J Biol Chem 1996; 271:17692-17734 (Pubitemid 26250731)
7. Adini A, Kornaga T, Firoozbakht F, Benjamin LE. Placenta growth factor is a survival factor for human endothelial cells and macrophages. Cancer Res 2002; 62:2749-2752 (Pubitemid 34525755)
8. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 1993; 8:925-931 (Pubitemid 23087424)
9. Cao Y, Ji WR, Qi P, Rosin A. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun 1997; 235:493-498 (Pubitemid 27326507)
10. Park J, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vivo and in vitro, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269:25646-25654 (Pubitemid 24982909)
11. Migdal M, Huppertz B, Tessler S, Comforti A, Shibuya M, Reich R, Baumann H, Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor. J Biol Chem 1998; 273:22272-22278 (Pubitemid 28399784)
12. Mamluk R, Gechtman Z, Kutcher ME, Gasiunas N, Gallagher J, Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2 and heparin via its b1b2 domain. J Biol Chem 2002; 277:24818-24825 (Pubitemid 34952014)
13. Cao Y, Chen H, Zhou L, et al. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 1996; 271:3154-3162 (Pubitemid 26060529)
14. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra- and intermolecular cross-talk between the VEGF receptors Flt-1 and Flk-1. Nat Med 2003; 9:936-943 (Pubitemid 36889938)
15. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-583 (Pubitemid 32448325)
16. Fisher C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8:942-956
17. Odorisio T, Schietroma C, Zaccaria ML, Cianfarani F, Tiveron C, Tatangelo L, Failla Cm, Zambruno G. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J Cell Sci 2002; 115:2559-2567 (Pubitemid 34778073)
18. Luttun A, Brusselmans K, Fukao H, et al. Loss of placenta growth factor protects mice against vascular permeability in pathological conditions. Biochem Biophys Res Commun 2002; 295:428-434 (Pubitemid 34785852)
19. Chen CN, Hsieh FJ, Cheng YM, Cheng WF, Su YN, Chang KJ, Lee PH. The significance of placenta growth factor in angiogenesis and clinical outcome of human gastric cancer. Cancer Lett 2004; 213:73-82. (Pubitemid 39118536)
20. Wei S-C, Tsao P-N, Yu S-C, Shun C-T, Tsai-Wu J-J, Wu CHH, Su Y-N, Hsieh F-J, Wong JM. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 2005; 54:666-72. (Pubitemid 40559252)
21. Parr C, Watkins G, Boulton M, Cai J, Jiang WG. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. Eur J Cancer 2005; 41:2819-2827 (Pubitemid 41713119)
22. Marcellini M, De Luca N, Riccioni T, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. Am J Pathol 2006; 169:643-654 (Pubitemid 44156320)
23. Fisher C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007; 131:463-475 (Pubitemid 350007692)
24. Cao Y, Linden P, Shima D, Browne F, Folkman J. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 1996; 98:2507-2511
25. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell 2002; 1:99-108. (Pubitemid 41039180)
26. Xu L, Cochran DM, Tong RT, Winkler F, Kashiwagi S, Jain RK, Fukumura D. Placenta growth factor overexpression inhibits tumor growth, angiogenesis and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models. Cancer Res 2006; 66:3971-3977
27. Schomber T, Kopfstein L, Djonov V, Albrecht I, Baeriswyl V, Strittmatter K, Christofori G. Placenta growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during â cell carcinogenesis. Cancer Res 2007; 67:10840-10848 (Pubitemid 350145913)
28. Pass H, Stevens EJ, Oie H, et al. Characteristic of nine newly derived mesothelioma cell lines. Ann Thor Surg 1995; 2:214-220
29. Orengo AM, Spoletini L, Procopio A, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis: Eur Respir J 1999; 13:527-534
30. Versnel MA, Bouts MJ, Hoogsteden HC, van der Kwast TH, Delahaye M, Hagemeijer A. Establishment of human malignant mesothelioma cell lines. Int J Cancer 1989; 44:256-260 (Pubitemid 19217211)
31. Bei R, Mentuccia D, Trono P, et al. Immunity to extracellular matrix antigens is associated with ultrastructural alterations of the stroma and stratified epithelium basement membrane in the skin of Hashimoto's thyroiditis patients. Int J Immunopathol Pharmacol 2006; 19:661-674 (Pubitemid 44580539)
32. Buttke TM, McCubrey JA, Owen TC. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 1993; 157:233-240 (Pubitemid 23028096)
33. Nishi J, Minamino T, Miyauchi H, et al. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt. Cire Res 2008; 103:261-8.
34. Marino M, Acconcia F, Trentalance A. Biphasic estradiol-induced Akt phosphorylation is modulated by PTEN via MAP kinase in HepG2 cells. Mol Biol Cell 2003; 14:2583-2591 (Pubitemid 36724344)
35. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor for human malignant mesothelioma. J Pathol 2001; 193:468-475 (Pubitemid 32266815)
36. Bielenberg DR, Pettaway CA, Takashima S, Klagsbrun M. Neuropilins in neoplasms: expression, regulation and function. 2005; Exp Cell Res 312:584-593
37. Cianfarani F, Zambruno G, Brogelli L, et al. Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am J Pathol 2006; 169:1167-1182 (Pubitemid 351194354)
38. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8:831-840. (Pubitemid 34887247)
39. Kerber M, Reiss Y, Wichersheim A, et al. Flt-1 signaling in macrophages promotes glioma growth in vivo. Cancer Res 2008; 68:7342-7351
40. Ponticelli S, Marasco D, Tarallo V, et al. modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem 2008; 283:34250-34259
41. Taylor AP, Goldenberg DM. Role of placenta growth factor in malignancy and evidence that an antagonistic PlGF/Flt-1 peptide inhibits the growth and metastasis of human breast cancer xenografts. Mol Cancer Ther 2007; 6:524-531 (Pubitemid 46332454)
42. Barillari G, Albonici L, Franzese O, et al. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into soluble form. Implication for tumor angiogenesis. Am J Pathol 1998; 152:1161-1166 (Pubitemid 28221868)
43. Holmes DIR, Zachary I. Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. FEBS Lett 2004; 557:93-98 (Pubitemid 38115875)
44. Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci 1993; 90:3299-3303 (Pubitemid 23111353)
45. Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res 2002; 62:6065-6069 (Pubitemid 35244454)